TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2352049
Drug: Middle Ear
Normalized name: middle ear inflation device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle Ear Implant (MEI)
Study: 2352049
Drug: Middle Ear
Normalized name: middle ear inflation device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle Ear Implant (MEI) and Hearing Aid (HA)
Study: 30021451
Drug: Process incentives
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Process incentives for attending weekly Diabetes Prevention Program sessions
Study: 30021451
Drug: Outcome incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Outcome incentives for achieving weekly weight loss goals
Study: 28542112
Drug: Vestibular rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular rehabilitation combined with conventional physical therapy (40 min + 20 min for 3 weeks, then 60 min conventional therapy for 3 weeks)
Study: 28542112
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (60 min for 6 weeks)
Study: 29367449
Drug: Zonisamide 25
Normalized name: zonisamide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide 25 mg once daily
Study: 15717651
Drug: APZ/AVP test
Approvals — FDA: no, EMA: no, PMDA: no
Description: APZ/AVP test (0.5 mg at midnight and 0.5 mg 90 min before the test)
Study: 15717651
Drug: APZ (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: APZ (0.5 mg at midnight and 0.5 mg 90 min before the test)
Study: 12097783
Drug: Fluoxetine 90
Normalized name: fluoxetine 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 90 mg twice a week
Study: 9817625
Drug: Sertraline or
Normalized name: sertraline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline or Citalopram
Study: 31906903
Drug: Mindfulness-integrated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-integrated cognitive behavior therapy (MiCBT)
Study: 31906903
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (wait-list control)
Study: 21966064
Drug: ramelteon (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramelteon (8 mg)
Study: 19786427
Drug: Maternal salivary
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal salivary cotinine levels (SCLs) > or =20 ng/mL
Study: 19786427
Drug: Maternal salivary
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal salivary cotinine levels (SCLs) > or =50 ng/mL
Study: 19786427
Drug: Maternal salivary
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal salivary cotinine levels (SCLs) > or =100 ng/mL
Study: 16679271
Drug: Dual-head power
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-head power injector using 0.6 mL/kg contrast flushed by 30 mL of saline solution (group D)
Study: 16679271
Drug: Single-head power
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-head power injector using 1.0 mL/kg contrast only (group S)
Study: 11505744
Drug: Enalapril (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5-20 mg once daily)
Study: 15811162
Drug: Ome‐Mg 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ome‐Mg 20 (20.6 mg omeprazole magnesium)
Study: 15811162
Drug: Ome‐Mg 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ome‐Mg 10 (10.3 mg omeprazole magnesium)
Study: 1668125
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg/day for three days
Study: 1668125
Drug: Itraconazole 400
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 400 mg acute dose
Study: 6958483
Drug: Budesonide administered
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide administered three hours before challenge
Study: 6958483
Drug: Budesonide administered
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide administered twice daily for one week before challenge
Study: 6958483
Drug: Budesonide (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (one week's treatment)
Study: 6958483
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered three hours before challenge
Study: 8105785
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one week's treatment)
Study: 31030867
Drug: Active psychological
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active psychological treatment (control)
Study: 24323549
Drug: CSL30 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL30 (30 ml kg(-1) crystalloid)
Study: 24323549
Drug: CSL10 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL10 (10 ml kg(-1) crystalloid)
Study: 14762857
Drug: Interferon and
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon and ribavirin combination therapy
Study: 11328902
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (ferrous sulphate 200 mg tds)
Study: 11328902
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (300 mg iron sucrose monthly)
Study: 8185690
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine A (CSA) - initial dosage 2.5 mg/kg/day, maintenance dosage 3.6 mg/kg/day
Study: 8185690
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) - initial dosage 300 mg/day, maintenance dosage 100 mg/day
Study: 3358238
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intramuscular streptomycin plus oral tetracycline over 14 days
Study: 3358238
Drug: 14-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day course of oral co-trimoxazole (trimethoprim-sulfamethoxazole)
Study: 21365126
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ITF2357 (givinostat)
Study: 21365126
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ITF2357 (givinostat)
Study: 21365126
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ITF2357 (givinostat)
Study: 21365126
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ITF2357 (givinostat)
Study: 21365126
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ITF2357 (givinostat)
Study: 21365126
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of 50 or 100 mg ITF2357 (givinostat)
Study: 26186592
Drug: Rikkunshito 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rikkunshito 7.5 g/day
Study: 9682339
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 0.1 ml of inactivated poliovirus vaccine (IPV) intradermally 8 weeks apart (group A)
Study: 9682339
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of inactivated poliovirus vaccine (IPV) intradermally 4 weeks apart (group B)
Study: 9682339
Drug: Infants without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants without pre-existing maternal antibody in both groups
Study: 7940114
Drug: ondansetron 32
Normalized name: ondansetron 32 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 32 mg iv 1 hour prior to treatment +/‐ corticosteroids
Study: 2510140
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 1000 mg aspirin as lysine salt
Study: 2510140
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 1000 mg aspirin as lysine salt
Study: 2510140
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 1000 mg aspirin as lysine salt
Study: 23351405
Drug: AHCC supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHCC supplementation (3 g/d)
Study: 11170993
Drug: Higher SLPI
Normalized name: SLPI
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher SLPI concentrations (>100 ng/mL)
Study: 11170993
Drug: Lower SLPI
Normalized name: SLPI
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower SLPI concentrations (<100 ng/mL)
Study: 7995992
Drug: Peru-3 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peru-3 vaccine strain
Study: 7995992
Drug: Peru-14 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peru-14 vaccine strain
Study: 170820
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (50% of calories) during period IV
Study: 170820
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (50% of calories) during period III
Study: 24737786
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (sulfasalazine+hydroxychloroquine)
Study: 24737786
Drug: Infliximab vs
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab vs Conventional treatment
Study: 21590485
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (primary fixation)
Study: 12514655
Drug: Coumarin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumarin group (aspirin plus coumarins started 1 week before the procedure)
Study: 12514655
Drug: ASA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA group (aspirin alone)
Study: 6270708
Drug: ACTH4-10 (Org
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH4-10 (Org O163) 30 mg
Study: 6270708
Drug: ACTH4-9 analog
Normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ACTH4-9 analog (Org 2766) dosages of 0.05 mg, 0.5 mg, and 5 mg
Study: 25377872
Drug: GSK1278863 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863 (300 mg single dose)
Study: 25377872
Drug: GSK1278863 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863 (15 mg daily for 14 days)
Study: 12895690
Drug: Soya supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya supplement (60 mg total isoflavone equivalents/day)
Study: 8811149
Drug: 3-mL syringe
Normalized name: glycopyrronium
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-mL syringe
Study: 8811149
Drug: 1-mL syringe
Normalized name: ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1-mL syringe
Study: 1577222
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (morning and bedtime famotidine)
Study: 3919579
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and parenteral antibiotic prophylaxis
Study: 3919579
Drug: Parenteral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antibiotic prophylaxis
Study: 12895219
Drug: Phyllanthus urinaris
Normalized name: Phyllanthus niruri top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus urinaris 1 g three times daily for 6 months
Study: 12895219
Drug: Phyllanthus urinaris
Normalized name: Phyllanthus niruri top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus urinaris 2 g three times daily for 6 months
Study: 12895219
Drug: Phyllanthus urinaris
Normalized name: Phyllanthus niruri top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus urinaris 3 g three times daily for 6 months
Study: 7587186
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral triphasic contraceptives
Study: 29543887
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg subcutaneously once every 6 months)
Study: 29543887
Drug: Alendronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (35 mg orally once a week)
Study: 15616290
Drug: Amoxicillin-clavulanate at
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate at 2,000/125 mg (5 days)
Study: 15616290
Drug: Amoxicillin-clavulanate at
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate at 875/125 mg (7 days)
Study: 8915932
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin G (IVIG) 750 mg/kg
Study: 8915932
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin G (IVIG)
Study: 1872270
Drug: Urokinase (1,000,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase (1,000,000 U intravenous bolus dose), followed by heparin infusion 3 hours later
Study: 1872270
Drug: Heparin (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (10,000 U intravenous bolus, followed by continuous infusion)
Study: 1872270
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy only (intravenous nitroglycerin, beta blockers and calcium antagonists)
Study: 31684759
Drug: Calcitonin gene-related
Normalized name: Calcitonin gene-related peptide
DrugBank: Calcitonin gene-related peptide (DB06379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin gene-related peptide (1.5 µg/min for 20 minutes)
Study: 31684759
Drug: Sildenafil (100 mg)
Normalized name: sildenafil 100 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil (100 mg)
Study: 25074387
Drug: Medium Chain
Normalized name: Medium chain triglyceride
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium Chain Triglycerides (MCT) 20 g
Study: 25074387
Drug: Long Chain
Normalized name: long chain triglycerides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long Chain Triglycerides (LCT) 20 g (corn oil)
Study: 17514424
Drug: Oral proton
Normalized name: Protonix Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral proton pump inhibitors (PPIs)
Study: 16318813
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of 100-120 mg BCG plus 100 mg para-aminomethyl benzoic acid (PAMBA)
Study: 16318813
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of 50-60 mg BCG plus 100 mg PAMBA
Study: 16318813
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of 100-120 mg BCG plus 2.0 g epsilon-aminocaproic acid (EACA)
Study: 16318813
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of 50-60 mg BCG plus 2.0 g EACA
Study: 16318813
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: 100-120 mg BCG
Study: 11942864
Drug: Albumin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin 40 g/L (7.1 mL/kg, i.e. 500 mL per 70 kg)
Study: 11942864
Drug: Dextran 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 30 g/L (7.1 mL/kg)
Study: 11942864
Drug: Ringer's acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate (21.4 mL/kg)
Study: 235837
Drug: Insulin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.2 U/kg body weight)
Study: 235837
Drug: Insulin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.2 U/kg body weight) + Bromazepam (0.1 mg/kg body weight) - subjects kept awake
Study: 235837
Drug: Insulin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.2 U/kg body weight) + Bromazepam (0.1 mg/kg body weight) - subjects allowed to sleep
Study: 372292
Drug: Nylidrin hydrochloride
Normalized name: nylidrin hydrochloride
DrugBank: Nylidrin (DB06152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nylidrin hydrochloride (24 mg daily)
Study: 22343798
Drug: Intravenous NAC
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous NAC
Study: 17040589
Drug: Co-phenylcaine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-phenylcaine administered for 10 minutes
Study: 17040589
Drug: Co-phenylcaine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-phenylcaine administered for 1 minute
Study: 11831546
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg atorvastatin coadministered with 2 mg everolimus
Study: 11831546
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pravastatin coadministered with 2 mg everolimus
Study: 11831546
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg everolimus alone
Study: 1923103
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside (Ara-C) 100 mg/m2 12 hourly for seven days and daunorubicin (DNR) 45 mg/m2 daily for three days followed by three further courses of Ara-C (five days) and DNR (two days) in the same dosage.
Study: 1923103
Drug: Three courses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three courses of VP16 100 mg/m2 daily for five days and one dose of mAMSA of 200 mg/m2 as postremission consolidation.
Study: 1923103
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment protocol.
Study: 30585454
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment (ginger-separated snake moxibustion), 3 cones per session, once a week for 12 weeks
Study: 27179849
Drug: Endobronchial coils
Normalized name: BOIL-EASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial coils treatment (n=158)
Study: 22103435
Drug: 1% nadifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% nadifloxacin combined with topical anti-acne products (adapalene, benzoyl peroxide, azelaic acid, isotretinoin)
Study: 22103435
Drug: Topical anti-acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anti-acne products (adapalene, benzoyl peroxide, azelaic acid, isotretinoin) alone
Study: 19021624
Drug: PNB combined
Normalized name: PNB
DrugBank: P-nitrobiphenyl (DB12300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNB combined with Antrolin cream (group B)
Study: 11833753
Drug: Immune-enhancing oral
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune-enhancing oral formula (Advera)
Study: 11833753
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral formula (Ensure Plus)
Study: 8583780
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low doses of HCTZ and furosemide (FU)
Study: 2182314
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality adjuvant therapy
Study: 342639
Drug: High-titer immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titer immune serum globulin (3-ml injections, two doses, four months apart)
Study: 342639
Drug: Low-titer immune
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-titer immune serum globulin (3-ml injections, two doses, four months apart)
Study: 23774314
Drug: High-dose corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroids (HDS; hydrocortisone, 100 mg, intravenously 3 times daily, followed by taper)
Study: 23774314
Drug: Low-dose corticosteroids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose corticosteroids (LDS; intravenous hydrocortisone equivalent to presurgical oral dosing, followed by taper)
Study: 22583760
Drug: Bivalirudin (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (bolus 0.75 mg/kg followed by infusion during the procedure; n = 198)
Study: 22583760
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH; 75 IU/kg; n = 203)
Study: 2344503
Drug: Bendrofluazide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 2.5 mg
Study: 8678264
Drug: hyaluronidase 150
Normalized name: hyaluronidase 1500 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyaluronidase 150 iu.ml‐1
Study: 8678264
Drug: hyaluronidase 50
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: hyaluronidase 50 iu.ml‐1
Study: 550143
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion during low sodium diet
Study: 550143
Drug: Dextrose and
Normalized name: Dextrose and Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose and water infusion during low sodium diet
Study: 550143
Drug: Indomethacin or
Normalized name: indomethacin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin or ibuprofen administration during saline and dextrose and water infusions